SONY

Product Data Sheet

Purified anti-human CD192 (CCR2)

Catalog # / Size:	2386005 / 25 µg 2386010 / 100 µg
Clone:	K036C2
Isotype:	Mouse IgG2a, κ
Immunogen:	CCR2 DNA immunogen
Reactivity:	Human
Preparation:	The antibody was purified by affinity chromatography.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration:	0.5



Human peripheral blood monocytes were stained with purified CCR2 (clone K036C2) (filled histogram) or purified mouse IgG2a, κ isotype control (open histogram), followed by anti-mouse IgG FITC.

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Description: CCR2 is a chemokine receptor that binds monocyte chemoattractant proteins (MCP-1, 2, 3 and 4). Two spliced variants were initially described for CCR2 (CCR2A and CCR2B). These variants differ in their terminal carboxyl tails. Monocyte adhesion to the arterial endothelium and subsequent migration into the intima are central events in the pathogenesis of atherosclerosis. CCR2 and MCP-1 have been associated to atherosclerotic plaques. MCP-1 is induced by modified-LDL in endothelial cells and may trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Local overexpression of MCP-1 at vessel walls induces infiltration of macrophages and formation of atherosclerotic lesions. Obesity induces an inflammatory state that is implicated in many clinically important complications, including insulin resistance, diabetes, atherosclerosis, and non-alcoholic fatty liver disease. CCR2 influences the development of obesity and associated adipose tissue inflammation.

Antigen References:

1. Wong LM, *et al.* 1997. *J. Biol. Chem.* 272:1038.
2. Papadopoulou C, *et al.* 2008. *Cytokine* 43:181.
3. Barlic J, *et al.* 2007. *J. Leukoc. Biol.* 82:226.
4. Gu L, et al. 1998. *Mol.*